Last August, U.S. Pain Foundation arranged for three patient representatives and one caregiver to speak about the challenges of osteoarthritis before senior officials at the U.S. Food and Drug Administration (FDA) in Silver Spring, MD.
FDA listening sessions are small, informal discussions about a disease state that can be either FDA-requested or patient-led (in this case, the latter). The sessions help FDA staff better understand patients’ experiences with a particular disease or condition.
On Aug. 7, a group of three U.S. Pain Foundation representatives with osteoarthritis (OA) and one caregiver joined Director of State Advocacy & Alliance Development Shaina Smith to speak about the challenges of the disease before senior officials within the U.S. Food and Drug Administration (FDA). The meeting was held at the FDA in Silver Spring, MD.
Earlier this year, U.S. Pain had requested the FDA’s Patient Affairs division host a patient listening session focusing on the unmet needs of patients with OA, which affects more than 30 million Americans. The FDA accepted the request, with 24 officials attending the listening session in-person and via conference call.
MIDDLETOWN, CONN. (Sept. 24, 2018)—This month sees the release of U.S. Pain’s latest issue of the INvisible Project, the only magazine of its kind dedicated to the sharing the stories of people living with pain. This issue focuses on osteoarthritis and chronic lower back pain, two of the most common causes of chronic pain, which affects as many as 100 million American adults. Due to that focus, this issue hopes to resonate with a record number of people.